EMA Sets Up Task Force To Offer Advice on Zika Research and Development
This article was originally published in SRA
Executive Summary
Following the announcement that the European Commission is to mobilize €10m for research into the mosquito-borne Zika virus, the European Medicines Agency has set up a dedicated expert task force to offer advice on R&D programs for medicines and vaccines, and is asking companies with potential projects to get in touch1.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.